Sökning: WFRF:(Eliasson M)
> (2010-2014) >
Lowering of postpra...
-
Eliasson, Björn,1959Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
(författare)
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
- Artikel/kapitelEngelska2012
Förlag, utgivningsår, omfång ...
-
2012-01-12
-
Springer Science and Business Media LLC,2012
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/152976
-
https://gup.ub.gu.se/publication/152976URI
-
https://doi.org/10.1007/s00125-011-2447-3DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-172025URI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
AIMS/HYPOTHESIS: Pharmacological augmentation of glucagon-like peptide 1 receptor signalling by dipeptidyl peptidase 4 (DPP-4) inhibition reduced intestinal lipoprotein secretion in experimental studies, suggesting that DPP-4 inhibitors may ameliorate dyslipidaemia and thus reduce cardiovascular risk in patients with type 2 diabetes. We assessed the effects of alogliptin (Alo) and Alo co-administered with pioglitazone (Pio) vs placebo (Pbo) on triacylglycerol (TG)-rich lipoproteins in type 2 diabetes before and following a high-fat meal. METHODS: Seventy-one patients (age 18-70years), who did not reach HbA(1c) 6.5% (48mmol/mol) with lifestyle and/or metformin, sulfonylurea or glinide therapy, participated in this 16week, double-centre (university hospitals) Pbo-controlled parallel-group study. All participants, people doing measurements or examinations, and people assessing the outcomes were blinded to group assignment. Fasting TG 1.7-5.0mmol/l was among the entry criteria. Patients received a high-fat mixed meal before and 4 and 16weeks after randomisation (allocation by central office) to Alo (n=25), Alo/Pio (n=22) or Pbo (n=24). Blood was sampled at pre-specified intervals, starting at 15min before and ending 8h after meal ingestion. RESULTS: At week 16, Alo (n=25) and Alo/Pio (n=21) vs Pbo (n=24) produced similar significant reductions in total postprandial TG response (incremental AUC [iAUC]; p<0.001), as well as in chylomicron TG (p<0.001) and VLDL1 TG iAUCs (p<0.001 and p=0.012, respectively). Postprandial chylomicron apolipoprotein B-48 iAUC showed a significant decrease after Alo treatment (p=0.028), and a non-significant trend towards a decrease with Alo/Pio (p=0.213). The incidence of adverse events was low and consistent with previous studies. CONCLUSIONS/INTERPRETATION: Treatment with Alo and Alo/Pio produced significant reductions in postprandial TG and TG-rich lipoproteins, contributing to an improved overall cardiometabolic risk profile in type 2 diabetes. The data support the concept that incretins not only modulate glucose metabolism but also influence chylomicron metabolism in intestinal cells. TRIAL REGISTRATION: ClinicalTrials.gov number NCT00655863. FUNDING: The study was funded by Takeda Global Research & Development.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Möller-Goede, D
(författare)
-
Eeg-Olofsson, Katarina,1968Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xeegka
(författare)
-
Wilson, C
(författare)
-
Cederholm, JanUppsala universitet,Allmänmedicin och preventivmedicin(Swepub:uu)janceder
(författare)
-
Fleck, P
(författare)
-
Diamant, M
(författare)
-
Taskinen, M-R
(författare)
-
Smith, Ulf,1943Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xsmiul
(författare)
-
Göteborgs universitetInstitutionen för medicin, avdelningen för molekylär och klinisk medicin
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Diabetologia: Springer Science and Business Media LLC55:4, s. 915-9251432-04280012-186X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Eliasson, Björn, ...
-
Möller-Goede, D
-
Eeg-Olofsson, Ka ...
-
Wilson, C
-
Cederholm, Jan
-
Fleck, P
-
visa fler...
-
Diamant, M
-
Taskinen, M-R
-
Smith, Ulf, 1943
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Diabetologia
- Av lärosätet
-
Göteborgs universitet
-
Uppsala universitet